In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction Associated Steatohepatitis (MASH) Related Fibrosis and Cirrhosis Mazdutide and Tirzepatide: How These Dual Pathway Weight Loss Drugs Really Compare Peptides Unleashed Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State of the Art Review Diabetes Therapy Springer Nature Link Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease